Biomarkers for peripheral artery disease
View Patent ↗This invention provides biomarkers whose concentrations in blood plasma are associated with the presence or absence of PAD in the patient from whom the plasma sample is taken. The invention also provides biomarkers for distinguishing between PAD patients who are long claudicators and PAD patients who are not. In addition, the invention provides methods for identifying additional biomarkers, methods for detecting the biomarkers in patients, and methods for identifying agents, including pharmaceutical agents, which interact with the biomarkers and are useful for preventing or treating PAD in patients.
1. A method for qualifying peripheral artery disease (PAM status in a subject comprising:
a. measuring α1β glycoprotein from said subject; and
b. correlating the measurement with PAD status.
2. The method of claim 1 , wherein step (a) is carried out on a sample obtained from a subject prior to exercise.
3. The method of claim 1 , further comprising measuring a second biomarker selected from the group consisting of albumin, fetuin, triple charge dieter of albumin, transthyretin, and dimer of α1-antitrypsin and correlating the measurement with PAD status.
4. The method of claim 1 , further comprising measuring each of: albumin, fetuin, triple charge dimer of albumin, transthyretin, and dimer of α1-antitrypsin.
5. The method of claim 1 , wherein α1β glycoprotein is measured by capturing the biomarker on an adsorbent surface of a SELDI probe and detecting the captured biomarkers by laser desorption-ionization mass spectrometry.
6. The method of claim 1 , wherein α1β glycoprotein is measured by immunoassay.
7. The method of claim 1 , wherein the sample is blood plasma.
8. The method claim 1 , wherein the correlating is performed by a software classification algorithm.
9. The method of claim 1 , wherein PAD status is selected from non-PAD, PAD, and long claudicator PAD.
10. A method for managing subject treatment based on PAD status, the method comprising qualifying a subject according to the method of claim 1 , and managing subject treatment based on the status.
11. The method of claim 10 , wherein PAD status is selected from non-PAD and PAD.
12. The method of claim 1 , wherein PAD status is selected from non-PAD and long claudicator PAD.
13. The method claim 1 , wherein PAD status is selected from PAD and long claudicator PAD.
14. The method of claim 5 , wherein the adsorbent is a cation exchange adsorbent.
15. The method of claim 9 , wherein, if the measurement correlates with PAD, then managing subject treatment comprises prescribing an exercise treatment regimen for the subject.
16. The method of claim 10 , further comprising measuring the at least one additional biomarker after subject management.
17. A method for qualifying PAD status in a subject comprising the method of claim 1 , wherein said subject is identified as having at least one symptom consistent with an increased likelihood that the subject will be afflicted with PAD.
18. A method for qualifying PAD status in a subject comprising the method of claim 17 , wherein said subject is identified as having at least one condition selected from cigarette smoking, hyperlipidemia, hypertension and family history of peripheral artery disease.